BridgeBio Pharma Inc (BBIO)
25.88
+0.27
(+1.05%)
USD |
NASDAQ |
Nov 07, 16:00
26.01
+0.13
(+0.50%)
After-Hours: 06:54
BridgeBio Pharma Revenue (TTM): 219.12M for June 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 219.12M |
| March 31, 2024 | 218.60M |
| December 31, 2023 | 9.303M |
| September 30, 2023 | 9.428M |
| June 30, 2023 | 5.675M |
| March 31, 2023 | 77.78M |
| December 31, 2022 | 77.65M |
| Date | Value |
|---|---|
| September 30, 2022 | 88.66M |
| June 30, 2022 | 90.67M |
| March 31, 2022 | 70.95M |
| December 31, 2021 | 69.72M |
| September 30, 2021 | 56.95M |
| June 30, 2021 | 62.74M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
5.675M
Minimum
Jun 2023
219.12M
Maximum
Jun 2024
81.33M
Average
70.95M
Median
Mar 2022
Revenue (TTM) Benchmarks
| Alnylam Pharmaceuticals Inc | 2.095B |
| Pfizer Inc | 59.37B |
| Vertex Pharmaceuticals Inc | 10.63B |
| PTC Therapeutics Inc | 900.45M |
| Bristol-Myers Squibb Co | 47.44B |